Bonita Rup

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

Rafael Ponce, Leslie W. Abad, Lakshmi Amaravadi et al. · Regulatory Toxicology and Pharmacology · 2009 · 268 citations

Pharmacy, Immunology, Pharmacokinetics +14

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

David A. Roth, Craig M. Kessler, John Pasi et al. · Blood · 2001 · 186 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

Raphael Schiffmann, Özlem Göker-Alpan, Myrl Holida et al. · Journal of Inherited Metabolic Disease · 2019 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Avian reticuloendotheliosis virus: Identification of the hematopoietic target cell for transformation

Robert B. Lewis, Janela McClure, Bonita Rup et al. · Cell · 1981 · 90 citations

Life Sciences, Hematology, Pathology +10

Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions

Sandeep Kumar, Satish Kumar Singh, Xiaoling Wang et al. · Pharmaceutical Research · 2011 · 85 citations

Life Sciences, Immunology, Pharmacology +10